Stock TAPIMMUNE INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News TapImmune Inc. OTC Bulletin Board

Equities

US8760332002

End-of-day quote OTC Bulletin Board
Other stock markets
- USD - Intraday chart for TapImmune Inc.
Mar. 27 North American Morning Briefing : Stocks Edge -2- DJ
Mar. 25 Marker Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies 
AQ
North American Morning Briefing : Stocks Edge -2-
DJ
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
AQ
Marker Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
AQ
North American Morning Briefing : Markets on Hold -2-
DJ
Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors
AQ
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601
AQ
Marker Therapeutics, Inc. Receives Approval from United States Adopted Name, Council and International Nonproprietary Names Expert Committee for ?Neldaleucel? as Nonproprietary Name for MT-601
CI
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
AQ
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
CI
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”
AQ
Top Midday Gainers
MT
Marker Therapeutics, Inc. Reports Clinical Update on the Apollo Study
CI
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
AQ
Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q3 Revenue $257.6M
MT
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
AQ
Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Marker Therapeutics, Inc. Announces Complete Response in First Lymphoma Patient Treated with MT-601 After Car T Relapse
CI
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRKR Stock
  4. Stock
  5. News TapImmune Inc.